Monograph Details
|
|
Central Nervous System
> ADHD/narcolepsy
|
|
DAYTRANA |
| Manufacturer |
|
Shire US, Inc. |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
CNS stimulant. |
| Generic Name |
|
Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9 hours; transdermal patches. |
| Indications |
|
Attention deficit hyperactivity disorder (ADHD). |
| Children |
|
<6 years: not recommended. 6–12 years: Initial: apply one 10mg patch to hip 2 hours before desired effect, remove 9 hours after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites. |
| Adults |
|
Not applicable. |
| Contraindications |
|
Marked anxiety, tension, agitation. Glaucoma. Motor tics. History of Tourette's syndrome in patient or family. During or within 14 days of MAOIs. |
| Precautions |
|
Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see literature). Avoid exposing patch to direct external heat sources. Structural cardiac abnormalities. Psychosis. Seizure disorders. EEG abnormalities. Hypertension. History of drug dependence or alcoholism. Monitor growth, BP, CBCs, differential, and platelet counts. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. May potentiate oral anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs. Caution with pressor agents, α2-agonists (eg, clonidine). |
| Adverse Reactions |
|
Application site reactions (eg, erythema), decreased appetite, insomnia, GI upset, weight loss, anorexia, nasal congestion, affect lability, tics, headache, irritability, nasopharyngitis, blurred vision (follow up if occurs). |
| How Supplied |
|
Patches—10, 30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
